Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 235

1.

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.

Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O.

Ann Rheum Dis. 2017 Oct 23. pii: annrheumdis-2017-211480. doi: 10.1136/annrheumdis-2017-211480. [Epub ahead of print]

PMID:
29061853
2.

Interstitial lung disease points to consider for clinical trials in systemic sclerosis.

Khanna D, Seibold J, Goldin J, Tashkin DP, Furst DE, Wells A.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203. Review.

PMID:
28992174
3.

Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Humbert M, Singh M, Furst DE, Khanna D, Seibold JR.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v33-v37. doi: 10.1093/rheumatology/kex197. Review.

PMID:
28992168
4.

Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames).

Seibold JR, Wigley FM.

Arthritis Rheumatol. 2017 Dec;69(12):2256-2258. doi: 10.1002/art.40307. Epub 2017 Nov 10. No abstract available.

PMID:
28859256
5.

Intentional Preparation of Auditory Attention-Switches: Explicit Cueing and Sequential Switch-Predictability.

Seibold JC, Nolden S, Oberem J, Fels J, Koch I.

Q J Exp Psychol (Hove). 2017 Jun 20:1-45. doi: 10.1080/17470218.2017.1344867. [Epub ahead of print]

PMID:
28631530
6.

Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP.

J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.

7.

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.

Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina E.

J Rheumatol. 2016 Sep;43(9):1672-9. doi: 10.3899/jrheum.151322. Epub 2016 Jul 1.

8.

Organ-sparing treatment of penile cancer with interstitial pulsed-dose-rate brachytherapy.

Seibold J, Strnad V, Fietkau R.

Strahlenther Onkol. 2016 Jul;192(7):467-72. doi: 10.1007/s00066-016-0968-x. Epub 2016 Jun 9.

PMID:
27276876
9.

Hypospadie. Kosmetisches Ergebnis nach operativer Korrektur.

Seibold J.

Aktuelle Urol. 2016 Feb;47(1):20-1. doi: 10.1055/s-0041-107490. Epub 2016 Feb 22. German. No abstract available.

PMID:
26903116
10.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Rheumatol. 2016 Feb;68(2):299-311. doi: 10.1002/art.39501.

11.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):167-78. doi: 10.1002/acr.22804.

12.

Exploring handedness asymmetries in the Simon effect.

Seibold JC, Chen J, Proctor RW.

Atten Percept Psychophys. 2016 Feb;78(2):437-51. doi: 10.3758/s13414-015-1037-8.

PMID:
26676871
13.

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group.

Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, Brown K, Flaherty K, Wells AU, Seibold JR, Strand V.

J Rheumatol. 2015 Nov;42(11):2168-71. doi: 10.3899/jrheum.141182. Epub 2015 Mar 1. Review.

14.

Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.

Wallace B, Kafaja S, Furst DE, Berrocal VJ, Merkel PA, Seibold JR, Mayes MD, Khanna D.

Rheumatology (Oxford). 2015 Aug;54(8):1369-79. doi: 10.1093/rheumatology/keu456. Epub 2015 Feb 9.

15.

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study.

Visovatti SH, Distler O, Coghlan JG, Denton CP, Grünig E, Bonderman D, Müller-Ladner U, Pope JE, Vonk MC, Seibold JR, Torres-Martin JV, Doelberg M, Chadha-Boreham H, Rosenberg DM, McLaughlin VV, Khanna D.

Arthritis Res Ther. 2014 Dec 10;16(6):493. doi: 10.1186/s13075-014-0493-1.

16.

Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.

Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, Cutolo M, Czirjak L, Denton CP, Distler O, Walker UA, Matucci-Cerinic M, Müller-Ladner U, Seibold JR, Singh M, Tyndall A.

Rheumatology (Oxford). 2015 Jan;54(1):144-51. doi: 10.1093/rheumatology/keu288. Epub 2014 Aug 13. Review.

17.

Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria.

Johnson SR, Naden RP, Fransen J, van den Hoogen F, Pope JE, Baron M, Tyndall A, Matucci-Cerinic M, Denton CP, Distler O, Gabrielli A, van Laar JM, Mayes M, Steen V, Seibold JR, Clements P, Medsger TA Jr, Carreira PE, Riemekasten G, Chung L, Fessler BJ, Merkel PA, Silver R, Varga J, Allanore Y, Mueller-Ladner U, Vonk MC, Walker UA, Cappelli S, Khanna D.

J Clin Epidemiol. 2014 Jun;67(6):706-14. doi: 10.1016/j.jclinepi.2013.12.009. Epub 2014 Apr 8.

18.

Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.

Wiese AB, Berrocal VJ, Furst DE, Seibold JR, Merkel PA, Mayes MD, Khanna D.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1731-9. doi: 10.1002/acr.22339.

19.

Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases.

Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group.

J Rheumatol. 2014 Apr;41(4):792-8. doi: 10.3899/jrheum.131251. Epub 2014 Feb 1. Review.

20.

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.

Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group.

Thorax. 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202. Epub 2013 Dec 24. Erratum in: Thorax. 2014 Sep;69(9):834. CTD-ILD Special Interest Group [added]; multiple investigator names added.

Supplemental Content

Loading ...
Support Center